Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK BROKER RATINGS: Goldman Sachs Says Buy Royal Mail And Intertek

Fri, 07th Nov 2014 09:42

LONDON (Alliance News) - The following UK shares received analyst recommendations Friday morning and Thursday afternoon:
----------
FTSE 100
----------
GOLDMAN RAISES BABCOCK INTERNATIONAL PRICE TARGET TO 1438 (1380) PENCE - 'BUY'
----------
GOLDMAN RESUMES ROYAL MAIL WITH 'BUY' - TARGET 575 PENCE
----------
GOLDMAN RAISES INTERTEK TO 'BUY' ('NEUTRAL') - TARGET 3440 (3240) PENCE
----------
GOLDMAN RAISES EXPERIAN TO 'NEUTRAL' ('SELL') - TARGET 1078 (985) PENCE
----------
TRADERS: NOMURA RAISES EXPERIAN PRICE TARGET TO 1,130 (1,100) PENCE - 'BUY'
----------
UBS CUTS COCA-COLA HBC TARGET TO 1,360 (1,450) PENCE - 'NEUTRAL'
----------
Nomura Cuts Coca-Cola HBC Price Target To 1,100p From 1,140p, Maintains Reduce
----------
UBS CUTS RSA INSURANCE PRICE TARGET TO 418 (427) PENCE - 'SELL'
----------
EXANE BNP RAISES RSA INSURANCE PRICE TARGET TO 430 (405) PENCE - 'UNDERPERFORM'
----------
UBS RAISES SCHRODERS PRICE TARGET TO 2,800 (2,400) PENCE - 'NEUTRAL'
----------
BERENBERG CUTS GLAXOSMITHKLINE PRICE TARGET TO 1540 (1575) PENCE - 'HOLD'
----------
CITIGROUP RAISES 3I GROUP PRICE TARGET TO 455 (430) PENCE - 'BUY'
----------
S&P CAPITAL IQ CUTS MORRISON TO 'SELL' ('HOLD') - TARGET 155 (195) PENCE
----------
LBBW RAISES ASTRAZENECA PRICE TARGET TO 3900 (3600) PENCE - 'SELL'
----------
NUMIS CUTS HSBC PRICE TARGET TO 700 (725) PENCE - 'ADD'
----------
NUMIS CUTS RANDGOLD RESOURCES PRICE TARGET TO 4,900 (5,100) PENCE - 'BUY'
----------
S&P CAPITAL IQ RAISES ASTRAZENECA PRICE TARGET TO 4700 (4500) PENCE - 'HOLD'
----------
FTSE 250
----------
GOLDMAN CUTS HAYS PRICE TARGET TO 153 (185) PENCE - 'BUY'
----------
TRADERS: GOLDMAN REMOVES HAYS FROM 'CONVICTION BUY LIST' - STILL 'BUY'
----------
GOLDMAN RAISES FIRSTGROUP PRICE TARGET TO 165 (160) PENCE - 'NEUTRAL'
----------
GOLDMAN RAISES BERENDSEN PRICE TARGET TO 1170 (1132) PENCE - 'NEUTRAL'
----------
GOLDMAN CUTS MICHAEL PAGE TO 'NEUTRAL' ('BUY') - TARGET 467 (570) PENCE
----------
GOLDMAN CUTS HIKMA PHARMA TO 'NEUTRAL' ('BUY') - TARGET 2120 (2250) PENCE
----------
MORGAN STANLEY RAISES WILLIAM HILL TARGET TO 460 (425) PENCE - 'OVERWEIGHT'
----------
TRADERS: SOCGEN CUTS AVEVA GROUP PRICE TARGET TO 2000 (2250) PENCE - 'BUY'
----------
CHARLES STANLEY RAISES COBHAM TO 'HOLD' ('REDUCE')
----------
BARCLAYS CUTS LONMIN PRICE TARGET TO 190 (205) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS CUTS HALFORDS GROUP PRICE TARGET TO 385 (400) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS CUTS LANCASHIRE HLDGS PRICE TARGET TO 494 (575) PENCE - 'UNDERWEIGHT'
----------
BARCLAYS INITIATES INFINIS ENERGY WITH 'OVERWEIGHT' - TARGET 275 PENCE
----------
TRADERS: JPMORGAN RAISES CRODA PRICE TARGET TO 2,300 (2,250) PENCE - 'NEUTRAL'
----------
HSBC CUTS JD WETHERSPOON PRICE TARGET TO 820 (850) PENCE - 'NEUTRAL'
----------
EXANE BNP CUTS TATE & LYLE PRICE TARGET TO 600 (610) PENCE - 'NEUTRAL'
----------
CITIGROUP RAISES BIG YELLOW GROUP PRICE TARGET TO 540 (470) PENCE - 'NEUTRAL'
----------
CITIGROUP CUTS UBM PRICE TARGET TO 670 (820) PENCE - 'BUY'
----------
CITIGROUP INITIATES POUNDLAND GROUP WITH 'BUY' - TARGET 350 PENCE
----------
TRADERS: JPMORGAN CUTS PLAYTECH TO 'NEUTRAL' ('OVERWEIGHT') - TARGET 615 (860) PENCE
----------
MAIN MARKET AND AIM
----------
CITIGROUP INITIATES B&M WITH 'BUY' - TARGET 310 PENCE
----------
PANMURE RAISES LOOKERS PRICE TARGET TO 175 (166) PENCE - 'BUY'
----------
PANMURE RAISES FILTRONIC PRICE TARGET TO 23 (20) PENCE - 'HOLD'
----------
TRADERS: JPMORGAN CUTS PROMETHEAN TO 'UNDERWEIGHT' ('NEUTRAL')
----------
TRADERS: JPMORGAN RAISES GEM DIAMONDS TARGET TO 280 (270) P - 'OVERWEIGHT'
----------
Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
18 Dec 2023 07:18

GSK sees success in Jemperli endometrial cancer trial

(Sharecast News) - GSK released positive headline results from the planned analysis of its trial of Jemperli in endometrial cancer on Monday.

Read more
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.